Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1794677 10.3389/fphar.2026.1794677 Retraction Retraction: Baicalin prevents myocardial ischemia/reperfusion injury through inhibiting ACSL4 mediated ferroptosis Frontiers Editorial Office 10.3389/fphar.2026.1794677 Frontiers Editorial Office * Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org 03 02 2026 2026 17 1794677 23 01 2026 23 01 2026 26 01 2026 Copyright © 2026 Frontiers Editorial Office. 2026 Frontiers Editorial Office https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Retraction of the Original Research Article Baicalin prevents myocardial ischemia/reperfusion injury through inhibiting acsl4 mediated ferroptosis by Fan Z, Cai L, Wang S, Wang J and Chen B (2021). Front. Pharmacol. 12:628988. doi: 10.3389/fphar.2021.628988 section-at-acceptance Cardiovascular and Smooth Muscle Pharmacology

The journal retracts the 14th of April 2021 article cited above.

Following publication, concerns were raised regarding the integrity of the data in the published Figure 1C, and the subsequent duplication 3 years later of this image (Figure1A) in another journal’s published article (Kardiologiia, 2024 October 31; 64 (10):48–56. doi: 10.18087/cardio.2024.10.n2739). The authors failed to provide the raw data or a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.

This retraction was approved by Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors have not responded to correspondence regarding this retraction.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland